Impact of the COVID-19 Pandemic on Radiotherapy Patterns of Practice for Curative Intent Breast Cancer Patients

Abstract

\n Purpose/Objective(s)\n In response to the COVID-19 pandemic, radiotherapy (RT) departments around the world created new policies as a means of reducing risk of exposure for patients and staff, while attempting to maintain high-quality RT. We aim to describe the impact of the pandemic on changes in breast cancer RT patterns of practice for new patient referrals at a tertiary cancer center.\n \n Materials/Methods\n Newly diagnosed breast cancer patients referred to our department from March 17-June 30, 2020 were included. Referrals for palliative RT were excluded. Demographic characteristics, COVID-19 status (if available) and RT treatment information, including deviations from usual practice because of the pandemic, were extracted from medical records by independent reviewers, and validated by the treating radiation oncologist. Descriptive statistics were used to summarize the data. The results were compared to breast cancer patients treated from March 17-June 30, 2019.\n \n Results\n A total of 271 and 306 patients met selection criteria for the 2020 and 2019 cohorts, respectively. The majority of consultations in 2020 were virtual (96%), conducted via telephone or videoconference, whereas in 2019 all were conducted in-person. Median age of the cohorts was similar: 58 years (range: 24-86) in 2020 and 59 years (range: 26-88) in 2019. Of those treated with adjuvant RT (n\u202f=\u202f209), 56% of patients received whole breast (WB), 36% regional nodal irradiation (RNI) and 8% partial breast (PB) RT in 2020, whereas in 2019 (n\u202f=\u202f284), 60% received WB, 31% RNI and 9% PB (Chi-squared test P\u202f=\u202f0.43). As a result of the pandemic, 78% of cases (n\u202f=\u202f211) received one or more deviations in RT practice compared to pre-pandemic institutional policies. The most common was an “altered dose/fractionation protocol” (n\u202f=\u202f197; 93%), such as use of hypofractionated RNI (2020: 97%, 74/76 cases vs. 2019: 3%, 3/87 cases) or the FAST Forward regimen (2020: 43%, 57/134 WB/PB cases vs. 2019: 0/197 cases). Other deviations included a delay in RT start (defined as > 12 weeks post-op) noted in 11% (n\u202f=\u202f29) and omission of RT in only 8% (n\u202f=\u202f17), both were recommended when the risks associated with COVID-19 were felt to outweigh the benefit of RT. One patient had a deviation in RT as a result of testing positive for COVID-19.\n \n Conclusion\n In order to minimize hospital visits in response to the COVID-19 pandemic, a substantial proportion of breast cancer patients were seen virtually and treated with newer hypofractionated dose schedules, while total omission of adjuvant RT was infrequently observed. Continuously tracking patterns of practice provides an opportunity to evaluate the impact of the pandemic on clinical outcomes and help inform post-pandemic value-enhancing practices.\n